Address

Novartis Venture Fund
100 Technology Square
Cambridge, MA 02139
United States

Open map

Novartis Venture Fund
c/o Novartis International AG
Postfach CH-4002
Basel
Switzerland

Open map

KANDO id: 42466

Corporate information

Also known as
Novartis Venture Fund
Registration country

Funding rounds

Investment preferences

Investment criteria
We are stage agnostic (seed to commercial companies) and invest in multiple therapeutic areas where there is clear unmet medical need. Our first step in the process is to review non-confidential information about the company, team, technology / data, financial and exit plan. The further evaluation of business proposals is then based on confidential presentations by the management team that starts the full due diligence process.

Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat.
Investment focus themes
Top investment portfolio themes
healthcare (1)  

Actual initial investment stage
N/A (2)

Investment activity status
Active investor

Selected investments

Displaying 26 - 50 of 83
Profile Country Funding
Visiogen Inc A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. N/A
Transform Pharmaceuticals Inc N/A
Torrey Pines Therapeutics Inc N/A
Theravance Inc N/A
Syrxx Inc N/A
Swiss Pharma Contract AG N/A
Speedel Holding AG N/A
ProCertus BioPharm Inc N/A
Silence Therapeutics PLC N/A
Oscient Pharmaceuticals Corp N/A
Neovacs SA N/A
Miikana Therapeutics Inc A clinically-driven oncology company founded out of the former Amgen Institute N/A
KuDOS Pharmaceuticals Ltd N/A
Kinetix Pharmaceuticals Inc N/A
IsoTis OrthoBiologics Inc N/A
Infinity Pharmaceuticals Inc Innovative drug discovery and development company. N/A
Idenix Pharmaceuticals Inc N/A
Anchor Therapeutics Inc N/A
Euthymics Bioscience Inc N/A
Diagnoplex Sarl N/A
Destiny Pharma N/A
Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. N/A
Covagen AG N/A
Celladon Corp N/A
Catalyst Biosciences Inc Developer of catalytic biopharmaceutical products based on engineered human proteases. N/A

Current team

Past employees

Selected Products / Customers

Financials